2
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
84
Expanded_access
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, T-Cell, Peripheral
1
Lymphoma
1
Interventions
3-Iodobenzylguanidine
9
Cyclophosphamide
6
Amifampridine
6
nilotinib
5
fludarabine
5
Magnetic Resonance Spectroscopy
5
trametinib
4
pembrolizumab
4
gallium 68 PSMA-11
4
fludarabine phosphate
4
elotuzumab
4
dabrafenib
4
Nivolumab
4
Bortezomib
4
Afatinib
4
venetoclax
3
regorafenib
3
midostaurin
3
TIC10 compound
3
Sunitinib
3
Prednisone
3
Lenalidomide
3
Ipilimumab
3
Everolimus
3
Dexamethasone
3
Crizotinib
3
Capecitabine
3
Axitinib
3
Alpelisib
3
Abiraterone Acetate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
tipifarnib
×
Clear all
NCT04809233
2025-06-04
Expanded Access to Tipifarnib
Kura Oncology, Inc.
Available